Business Description
Lineage Cell Therapeutics Inc
NAICS : 541713
SIC : 2836
ISIN : US09066L1052
Total Employee Number:
77Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 22.3 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.11 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.09 | |||||
Beneish M-Score | -0.32 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -10.2 | |||||
3-Year EBITDA Growth Rate | 10.4 | |||||
3-Year EPS without NRI Growth Rate | 15.2 | |||||
3-Year Book Growth Rate | -24.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 42.54 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.27 | |||||
9-Day RSI | 46.95 | |||||
14-Day RSI | 48.84 | |||||
3-1 Month Momentum % | -15.32 | |||||
6-1 Month Momentum % | -27.59 | |||||
12-1 Month Momentum % | 25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.89 | |||||
Quick Ratio | 6.89 | |||||
Cash Ratio | 6.55 | |||||
Days Sales Outstanding | 11.33 | |||||
Days Payable | 5935.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.6 | |||||
Shareholder Yield % | -6.45 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.26 | |||||
Operating Margin % | -154.73 | |||||
Net Margin % | -434.44 | |||||
EBITDA Margin % | -149.83 | |||||
FCF Margin % | -153.51 | |||||
OCF Margin % | -150.27 | |||||
ROE % | -129.51 | |||||
ROA % | -62.42 | |||||
ROIC % | -37.84 | |||||
3-Year ROIIC % | -16.04 | |||||
ROC (Joel Greenblatt) % | -521.74 | |||||
ROCE % | -24.77 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 20.32 | |||||
PB Ratio | 5.93 | |||||
Price-to-Tangible-Book | 27.83 | |||||
EV-to-EBIT | -11.67 | |||||
EV-to-Forward-EBIT | -12.47 | |||||
EV-to-EBITDA | -12.05 | |||||
EV-to-Forward-EBITDA | -10.23 | |||||
EV-to-Revenue | 18.06 | |||||
EV-to-Forward-Revenue | 25.8 | |||||
EV-to-FCF | -11.82 | |||||
Price-to-GF-Value | 0.99 | |||||
Price-to-Median-PS-Value | 0.23 | |||||
Earnings Yield (Greenblatt) % | -8.57 | |||||
FCF Yield % | -7.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lineage Cell Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 12.668 | ||
| EPS (TTM) (€) | -0.25 | ||
| Beta | 1.0751 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.3 | ||
| Volatility % | 65.15 | ||
| 14-Day RSI | 48.84 | ||
| 14-Day ATR (€) | 0.05306 | ||
| 20-Day SMA (€) | 1.1106 | ||
| 12-1 Month Momentum % | 25 | ||
| 52-Week Range (€) | 0.72 - 1.66 | ||
| Shares Outstanding (Mil) | 249.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lineage Cell Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lineage Cell Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 119 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | In 33 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 32 days | ||
| General meeting for 2026 | 2026-06-10 08:00 | 1.04 (+2.35%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 1.11 (-3.15%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 1.11 (-3.15%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 16:30 | 1.65 (+4.43%) | ||
| Annual report for 2025 | 2026-03-05 | 1.65 (+4.43%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 1.65 (+4.43%) |
Show
Entries
Lineage Cell Therapeutics Inc Frequently Asked Questions
What is Lineage Cell Therapeutics Inc(STU:BT3)'s stock price today?
The current price of STU:BT3 is €1.11. The 52 week high of STU:BT3 is €1.66 and 52 week low is €0.72.
When is next earnings date of Lineage Cell Therapeutics Inc(STU:BT3)?
The next earnings date of Lineage Cell Therapeutics Inc(STU:BT3) is 2026-08-12 Est..
Does Lineage Cell Therapeutics Inc(STU:BT3) pay dividends? If so, how much?
Lineage Cell Therapeutics Inc(STU:BT3) does not pay dividend.
Press Release
Articles on Lineage Cell Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers